Sun Pharmaceutical Industries 관리
관리 기준 확인 4/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Dilip Shanghvi
최고 경영자
₹60.5m
총 보상
| CEO 급여 비율 | 75.6% |
| CEO 임기 | 31.7yrs |
| CEO 소유권 | 9.6% |
| 경영진 평균 재임 기간 | 2.8yrs |
| 이사회 평균 재임 기간 | 3.5yrs |
최근 관리 업데이트
Recent updates
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹111b |
| Jun 30 2024 | n/a | n/a | ₹104b |
| Mar 31 2024 | ₹61m | ₹46m | ₹96b |
| Dec 31 2023 | n/a | n/a | ₹89b |
| Sep 30 2023 | n/a | n/a | ₹85b |
| Jun 30 2023 | n/a | n/a | ₹84b |
| Mar 31 2023 | ₹55m | ₹41m | ₹85b |
| Dec 31 2022 | n/a | n/a | ₹42b |
| Sep 30 2022 | n/a | n/a | ₹41b |
| Jun 30 2022 | n/a | n/a | ₹39b |
| Mar 31 2022 | ₹51m | ₹38m | ₹33b |
| Dec 31 2021 | n/a | n/a | ₹64b |
| Sep 30 2021 | n/a | n/a | ₹62b |
| Jun 30 2021 | n/a | n/a | ₹60b |
| Mar 31 2021 | ₹46m | ₹35m | ₹29b |
| Dec 31 2020 | n/a | n/a | ₹24b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹7b |
| Mar 31 2020 | ₹43m | ₹32m | ₹38b |
| Dec 31 2019 | n/a | n/a | ₹40b |
| Sep 30 2019 | n/a | n/a | ₹43b |
| Jun 30 2019 | n/a | n/a | ₹30b |
| Mar 31 2019 | ₹263k | ₹1 | ₹27b |
| Dec 31 2018 | n/a | n/a | ₹34b |
| Sep 30 2018 | n/a | n/a | ₹24b |
| Jun 30 2018 | n/a | n/a | ₹36b |
| Mar 31 2018 | ₹34m | ₹28m | ₹21b |
보상 대 시장: Dilip 의 총 보상 ($USD 717.00K ) Indian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.10M ).
보상과 수익: Dilip 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Dilip Shanghvi (69 yo)
31.7yrs
테뉴어
₹60,541,920
보상
Mr. Dilip Shantilal Shanghvi serves as MD at Sun Petrochemicals Private Limited. He serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He se...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| MD & Chairman of the Board | no data | ₹60.54m | 9.6% ₹ 413.6b | |
| Executive VP | no data | ₹68.75m | 0.12% ₹ 5.2b | |
| Chief Financial Officer | 7.4yrs | ₹38.89m | 데이터 없음 | |
| Executive Vice-President of Global Operations | no data | 데이터 없음 | 데이터 없음 | |
| EVP & Chief Information Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| VP, Head of Investor Relations & Strategic Projects | no data | 데이터 없음 | 데이터 없음 | |
| Company Secretary & Compliance Officer | 2.8yrs | 데이터 없음 | 데이터 없음 | |
| Director of Corporate Development | no data | ₹65.30m | 데이터 없음 | |
| Chief Human Resources Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Head of India Business | no data | 데이터 없음 | 데이터 없음 | |
| Chief Executive Officer of North America Business | 8.3yrs | 데이터 없음 | 데이터 없음 | |
| Head of Corporate Relations & CSR - India Regulatory Affairs | no data | 데이터 없음 | 데이터 없음 |
2.8yrs
평균 재임 기간
60yo
평균 연령
경험이 풍부한 관리: SUNPHARMA 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| MD & Chairman of the Board | 31.7yrs | ₹60.54m | 9.6% ₹ 413.6b | |
| Executive VP | 1.4yrs | ₹68.75m | 0.12% ₹ 5.2b | |
| Non-Executive & Non-Independent Director | 30.8yrs | ₹2.20m | 1.8% ₹ 77.5b | |
| Non-Executive & Independent Director | 3.5yrs | ₹5.10m | 데이터 없음 | |
| Non-Executive Independent Director | 6.5yrs | ₹7.80m | 데이터 없음 | |
| Independent Director | 1.4yrs | ₹3.20m | 데이터 없음 | |
| Lead Independent Director | 3.5yrs | ₹8.50m | 데이터 없음 | |
| Independent Director | 2yrs | ₹4.80m | 데이터 없음 |
3.5yrs
평균 재임 기간
67.5yo
평균 연령
경험이 풍부한 이사회: SUNPHARMA 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.